June 13, 2018
Exosome Diagnostics Achieves ISO 13485:2016 Certification
May 22, 2018
Exosome Diagnostics Announces Bladder Cancer Surveillance Panel: The First Liquid Biopsy Designed Entirely By Artificial Intelligence (AI)
May 17, 2018
Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CAMay 15, 2018
May 15, 2018
Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain
May 9, 2018
Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test
May 8, 2018
Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test
April 17, 2018
Exosome Diagnostics Obviates Tissue Biopsies
March 21, 2018
Exosome Diagnostics Appoints Accomplished Urologist, Grannum Sant, MD, FRCS, FACS, as Head of Medical Affairs
March 20, 2018
Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients
March 13, 2018
Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor
February 23, 2018
Exosome Diagnostics Expands its Coverage Reach for EPI to an Additional 82 Million Covered Lives in the United States
February 1, 2018
Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed
UPCOMING EVENTS
Now available to Heathcare Providers for Clinical Use: The Industry’s First Exosome-Based Liquid Biopsy Tests
Order Here
The Industry’s First RNA-Based Liquid Biopsies
We are bringing the first exosome-based diagnostics to market. Learn more about our Laboratory Developed Tests, which will be analyzed in our CLIA-certified laboratory:
